Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Atafenovir vs Arbidol in Healthy Male Subjects
NCT04476719Phase 1Unknown
- Sponsor
- Atabay Kimya
- Start
- Jul 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of umifenovir in influenza (2 arms), sponsored by Atabay Kimya. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration. Status: unknown.
02
Drugs
umifenovir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04476719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476719.